2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
LXR / ApoE · Literature evidence
Biological Activity
RGX-104 is an LXR agonist for studying myeloid-derived suppressor cells, ApoE signaling and tumor immune responses. ApoE mediated the depletion of immunosuppressive myeloid cells and supported cytotoxic T-cell responses.
In Vitro
Endpoint
Model / conditions / source
Reported result
Mechanistic framework
LXR/ApoE pathway interrogated using genetic and pharmacological approaches. [1]
ApoE mediated the depletion of immunosuppressive myeloid cells and supported cytotoxic T-cell responses.
In Vivo
Endpoint
Model / conditions / source
Reported result
Preclinical pathway evidence
Multiple murine tumor models with LXR-directed interventions. [1]
LXR/ApoE activation reduced MDSC abundance and enhanced antitumor immune responses. Compound and combination arms must be distinguished.
